PE20080738A1 - Sistema de liberacion controlada y metodo para fabricarlo - Google Patents
Sistema de liberacion controlada y metodo para fabricarloInfo
- Publication number
- PE20080738A1 PE20080738A1 PE2007001080A PE2007001080A PE20080738A1 PE 20080738 A1 PE20080738 A1 PE 20080738A1 PE 2007001080 A PE2007001080 A PE 2007001080A PE 2007001080 A PE2007001080 A PE 2007001080A PE 20080738 A1 PE20080738 A1 PE 20080738A1
- Authority
- PE
- Peru
- Prior art keywords
- layer
- controlled release
- release system
- etilcellulose
- optionally
- Prior art date
Links
- 238000013270 controlled release Methods 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 229920000642 polymer Polymers 0.000 abstract 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 abstract 2
- 239000003607 modifier Substances 0.000 abstract 2
- 150000000996 L-ascorbic acids Chemical class 0.000 abstract 1
- XLYOFNOQVPJJNP-PWCQTSIFSA-N Tritiated water Chemical compound [3H]O[3H] XLYOFNOQVPJJNP-PWCQTSIFSA-N 0.000 abstract 1
- 150000001243 acetic acids Chemical class 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000000872 buffer Substances 0.000 abstract 1
- 229910000019 calcium carbonate Inorganic materials 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000011162 core material Substances 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- PPRRDFIXUUSXRA-UHFFFAOYSA-N flibanserin Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCN3C(NC4=CC=CC=C43)=O)CC2)=C1 PPRRDFIXUUSXRA-UHFFFAOYSA-N 0.000 abstract 1
- 229960002053 flibanserin Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000007524 organic acids Chemical group 0.000 abstract 1
- 235000005985 organic acids Nutrition 0.000 abstract 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 abstract 1
- 229920003176 water-insoluble polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
REFERIDA A UN SISTEMA DE LIBERACION CONTROLADA QUE COMPRENDE: a) UN MATERIAL DE NUCLEO QUE COMPRENDE UNO O MAS MODIFICAODRES DE pH, b) OPCIONALMENTE UNA CAPA AISLANTE, c) UNA PRIMERA CAPA QUE COMPRENDE UNO O MAS POLIMEROS INSOLUBLES EN AGUA, d) UNA SEGUNDA CAPA QUE COMPRENDE POR LO MENOS UNA SUSTANCIA ACTIVA QUE TIENE UNA SOLUBILIDAD DEPENDIENTE DEL pH, e) UNA TERCERA CAPA QUE COMPRENDE UNO O MAS POLIMEROS QUE TIENEN GRUPOS ANIONICOS O NO IONICOS Y f) OPCIONALMENTE UNA CUARTA CAPA. EL MODIFICADOR DE pH SE SELECCIONA DE ACIDOS ORGANICOS TAL COMO ACIDO ACETICO, ASCORBICO, ENTRE OTROS, UNA O MAS BASES, UNO O MAS TAMPONES TAL COMO CARBONATO DE CALCIO, FOSFATO DE CALCIO TRIBASICO, ENTRE OTROS Y MEZCLAS DE LOS MISMOS; DE PREFERENCIA EL POLIMERO INSOLUBLE EN AGUA ES ETILCELULOSA; EL POLIMERO DE LA TERCERA CAPA PUEDE SER ETILCELULOSA, HIDROXIPROPILMETILCELULOSA FTALATO, ENTRE OTROS; EL COMPUESTO ACTIVO ES FLIBANSERINA. TAMBIEN ESTA REFERIDA A UN METODO DE PREPARACION
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06017754 | 2006-08-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20080738A1 true PE20080738A1 (es) | 2008-08-05 |
Family
ID=38596345
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2007001080A PE20080738A1 (es) | 2006-08-25 | 2007-08-13 | Sistema de liberacion controlada y metodo para fabricarlo |
Country Status (19)
Country | Link |
---|---|
US (1) | US8512748B2 (es) |
EP (1) | EP2056797A2 (es) |
JP (1) | JP5220746B2 (es) |
KR (1) | KR20090045945A (es) |
CN (2) | CN104721168A (es) |
AR (1) | AR062321A1 (es) |
AU (1) | AU2007287639A1 (es) |
BR (1) | BRPI0716436B8 (es) |
CA (1) | CA2661613C (es) |
CL (1) | CL2007002358A1 (es) |
CO (1) | CO6150131A2 (es) |
EA (1) | EA200900270A1 (es) |
IL (1) | IL197129A (es) |
MX (1) | MX2009002031A (es) |
NO (1) | NO20090100L (es) |
PE (1) | PE20080738A1 (es) |
TW (1) | TW200817053A (es) |
WO (1) | WO2008022932A2 (es) |
ZA (1) | ZA200810781B (es) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7183410B2 (en) * | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
US20030060475A1 (en) * | 2001-08-10 | 2003-03-27 | Boehringer Ingelheim Pharma Kg | Method of using flibanserin for neuroprotection |
US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
US20040048877A1 (en) * | 2002-05-22 | 2004-03-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions containing flibanserin |
PA8578501A1 (es) * | 2002-07-25 | 2005-02-04 | Pharmacia Corp | Forma de dosificacion una vez al dia de pramipexol |
BRPI0510074A (pt) * | 2004-04-22 | 2007-10-16 | Boehringer Ingelheim Int | composições farmacêuticas para o tratamento de distúrbios sexuais ii |
US20050239798A1 (en) * | 2004-04-22 | 2005-10-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for the treatment of premenstrual and other female sexual disorders |
US20060025420A1 (en) * | 2004-07-30 | 2006-02-02 | Boehringer Ingelheimn International GmbH | Pharmaceutical compositions for the treatment of female sexual disorders |
CA2576386A1 (en) * | 2004-08-13 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
BRPI0513846A (pt) * | 2004-08-13 | 2008-05-20 | Boehringer Ingelheim Int | formulação de comprimido de liberação prolongada contendo pramipexol ou um sal farmaceuticamente aceitável do mesmo, método para a fabricação do mesmo e o uso do mesmo |
WO2006024471A1 (en) * | 2004-09-03 | 2006-03-09 | Boehringer Ingelheim International Gmbh | Method for the treatment of attention deficit hyperactivity disorder |
WO2006096439A2 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases |
CA2599721A1 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of depression |
WO2006096434A2 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders |
WO2006119884A2 (en) * | 2005-05-06 | 2006-11-16 | Boehringer Ingelheim International Gmbh | Method for the treatment of drug abuse with flibanserin |
JP2008540673A (ja) * | 2005-05-19 | 2008-11-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 薬剤誘発性性機能不全の治療方法 |
EP1888070A1 (en) * | 2005-05-19 | 2008-02-20 | Boehringer Ingelheim International GmbH | Method for the treatment of sexual dysfunctions due to medical conditions |
ES2646326T3 (es) | 2005-08-03 | 2017-12-13 | Sprout Pharmaceuticals, Inc. | Uso de flibanserina en el tratamiento de la obesidad |
CA2626134C (en) | 2005-10-29 | 2013-12-24 | Boehringer Ingelheim International Gmbh | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
WO2007090881A2 (en) * | 2006-02-10 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Modified release formulation |
WO2007090883A1 (en) * | 2006-02-10 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Extended release formulation |
JP2009536176A (ja) * | 2006-05-09 | 2009-10-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 閉経後の性的欲求障害の治療のためのフリバンセリンの使用 |
DE602007004615D1 (de) | 2006-06-30 | 2010-03-18 | Boehringer Ingelheim Pharma | Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen |
WO2008006838A1 (en) * | 2006-07-14 | 2008-01-17 | Boehringer Ingelheim International Gmbh | Use of flibanserin for the treatment of sexual disorders in females |
AR062320A1 (es) | 2006-08-14 | 2008-10-29 | Boehringer Ingelheim Int | Formulaciones de flibanserina y metodo para fabricarlas |
CL2007002214A1 (es) * | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
EA200900270A1 (ru) | 2006-08-25 | 2009-08-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Системы регулируемого высвобождения и способ их приготовления |
ATE524446T1 (de) | 2006-12-20 | 2011-09-15 | Boehringer Ingelheim Int | Sulfatierte benzimidazolon-derivate mit gemischter serotonin-rezeptor-affinität |
JP5087011B2 (ja) * | 2007-01-23 | 2012-11-28 | 馨 井上 | 眼疾患モデル用非ヒト動物 |
CL2008002693A1 (es) | 2007-09-12 | 2009-10-16 | Boehringer Ingelheim Int | Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad |
EP2090297A1 (en) * | 2008-02-13 | 2009-08-19 | Boehringer Ingelheim International GmbH | Formulations of flibanserin |
WO2009118321A1 (de) * | 2008-03-28 | 2009-10-01 | Boehringer Ingelheim International Gmbh | Verfahren zur herstellung von säurepellets |
CA2686480A1 (en) | 2008-12-15 | 2010-06-15 | Boehringer Ingelheim International Gmbh | New salts |
JP5801826B2 (ja) * | 2010-03-01 | 2015-10-28 | ラティオファルム ゲー・エム・ベー・ハー | ダビガトランエテキシラートを含有する経口用医薬組成物 |
CN102917695A (zh) * | 2010-04-09 | 2013-02-06 | 百时美施贵宝公司 | 具有改进的pH效应的阿扎那韦硫酸盐制剂 |
CN102958470B (zh) * | 2010-07-09 | 2016-04-20 | 斯恩蒂斯有限公司 | 用于易于除去植入体的自分离层 |
AR086913A1 (es) * | 2011-06-14 | 2014-01-29 | Novartis Ag | 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas |
CA2876200A1 (en) * | 2012-06-14 | 2013-12-19 | Allied Blending & Ingredients, Inc. | Method of treating a divided cheese product for anticaking and compositions thereof |
US20130345262A1 (en) | 2012-06-25 | 2013-12-26 | Boehringer Ingelheim International Gmbh | Method for prevention of stroke |
DK2916824T3 (da) * | 2012-11-12 | 2019-09-30 | New Jersey Inst Technology | Farmaceutisk kerne-skal-kompositpulver og fremgangsmåder til fremstilling af samme |
EP2853260A1 (en) | 2013-09-27 | 2015-04-01 | ratiopharm GmbH | Pharmaceutical preparation comprising dabigatran etexilate bismesylate |
GB201416293D0 (en) | 2014-09-15 | 2014-10-29 | Solvotrin Therapeutics Ltd | Methods and preparations |
AU2015346037A1 (en) | 2014-11-14 | 2017-07-06 | Gemphire Therapeutics Inc. | Processes and intermediates for preparing alpha,omega-dicarboxylic acid-terminated dialkane ethers |
EP3167879A1 (en) * | 2015-11-10 | 2017-05-17 | Evonik Technochemie GmbH | Gastric retention active delivery systems |
US9668991B1 (en) * | 2015-12-09 | 2017-06-06 | International Business Machines Corporation | SCFA colonic composition |
US11224615B2 (en) * | 2016-03-15 | 2022-01-18 | Solvotrin Therapeutics Ltd | Compositions and methods for increasing iron intake in a mammal |
US11033039B2 (en) | 2017-04-26 | 2021-06-15 | Allied Blending LP | Methods for treating a divided cheese product and compositions thereof |
WO2018209257A1 (en) * | 2017-05-11 | 2018-11-15 | Gemphire Therapeutics Inc. | Gemcabene compositions and methods of use thereof |
CN110251475B (zh) * | 2019-07-25 | 2021-07-16 | 沈阳信康药物研究有限公司 | 一种帕利哌酮片剂及其制备方法 |
US10624361B1 (en) | 2019-09-20 | 2020-04-21 | Allied Blending LP | Methods for treating a divided cheese product and compositions thereof |
EP4033912A4 (en) * | 2019-09-27 | 2023-10-18 | Hercules LLC | TITANIUM DIOXIDE-FREE WHITE FILM COATING COMPOSITION, PREPARATION METHOD THEREFOR AND METHOD OF USE |
Family Cites Families (129)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3096248A (en) * | 1959-04-06 | 1963-07-02 | Rexall Drug & Chemical Company | Method of making an encapsulated tablet |
US3406178A (en) * | 1964-02-04 | 1968-10-15 | Monsanto Chem Australia Ltd | Preparation of 2-substituted benzimidazoles |
US3362956A (en) * | 1965-08-19 | 1968-01-09 | Sterling Drug Inc | 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines |
US4200641A (en) * | 1976-12-21 | 1980-04-29 | Janssen Pharmaceutica, N.V. | 1-[(Heterocyclyl)-alkyl]-4-diarylmethoxy piperidine derivatives |
FI791926A (fi) | 1978-06-20 | 1979-12-21 | Synthelabo | Fenylpiperazinderivat |
DE3000979A1 (de) * | 1980-01-12 | 1981-07-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue dipyridamol-retardformen und verfahren zu ihrer herstellung |
IT1176613B (it) * | 1984-08-14 | 1987-08-18 | Ravizza Spa | Derivati piperazinici farmacologicamente attivi e processo per la loro preparazione |
IE58370B1 (en) | 1985-04-10 | 1993-09-08 | Lundbeck & Co As H | Indole derivatives |
GB8607294D0 (en) * | 1985-04-17 | 1986-04-30 | Ici America Inc | Heterocyclic amide derivatives |
HUT43600A (en) * | 1985-06-22 | 1987-11-30 | Sandoz Ag | Process for production of new thiazole derivatives and medical compound containing those |
DE3620643A1 (de) | 1985-06-22 | 1987-01-22 | Sandoz Ag | Thiazole, ihre herstellung und verwendung |
GB8601160D0 (en) * | 1986-01-17 | 1986-02-19 | Fujisawa Pharmaceutical Co | Heterocyclic compounds |
US5036088A (en) * | 1986-06-09 | 1991-07-30 | Pfizer Inc. | Antiallergy and antiinflammatory agents, compositions and use |
JPH0784462B2 (ja) * | 1986-07-25 | 1995-09-13 | 日清製粉株式会社 | ベンゾイミダゾ−ル誘導体 |
US4968508A (en) * | 1987-02-27 | 1990-11-06 | Eli Lilly And Company | Sustained release matrix |
US4792452A (en) * | 1987-07-28 | 1988-12-20 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
GB8830312D0 (en) | 1988-12-28 | 1989-02-22 | Lundbeck & Co As H | Heterocyclic compounds |
US4954503A (en) * | 1989-09-11 | 1990-09-04 | Hoechst-Roussel Pharmaceuticals, Inc. | 3-(1-substituted-4-piperazinyl)-1H-indazoles |
AU8629691A (en) | 1990-08-09 | 1992-03-02 | Massachusetts Institute Of Technology | Method for treating the premenstrual or late luteal phase syndrome |
CA2071488C (en) | 1990-08-24 | 1996-05-07 | Kazuto Kobayashi | Base for film-coating pharmaceuticals and method for preparing same |
NZ241613A (en) * | 1991-02-27 | 1993-06-25 | Janssen Pharmaceutica Nv | Highlighting intagliations in tablets |
SE9100860D0 (sv) * | 1991-03-22 | 1991-03-22 | Kabi Pharmacia Ab | New use |
FR2675800A1 (fr) | 1991-04-26 | 1992-10-30 | Rhone Poulenc Rorer Sa | Derives heterocycliques antiserotonines leur preparation et les medicaments les contenant. |
IT1251144B (it) * | 1991-07-30 | 1995-05-04 | Boehringer Ingelheim Italia | Derivati del benzimidazolone |
US5407686A (en) * | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
US5225417A (en) * | 1992-01-21 | 1993-07-06 | G. D. Searle & Co. | Opioid agonist compounds |
US5492907A (en) * | 1992-12-09 | 1996-02-20 | The United States Of America As Represented By The Department Of Health & Human Services | Antipsychotic composition and method of treatment |
FR2707294B1 (fr) * | 1993-07-06 | 1995-09-29 | Pf Medicament | Nouveaux dérivés de la 3,5-dioxo-(2H,4H)-1,2,4-triazine, leur préparation et leur application en thérapeutique humaine. |
DE4332394A1 (de) * | 1993-09-23 | 1995-03-30 | Falk Pharma Gmbh | Budesonid-Pellets mit kontrolliertem Freigabeprofil und Verfahren zu ihrer Herstellung |
GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
ATE206708T1 (de) | 1994-06-14 | 2001-10-15 | Pfizer | Benzimidazolonderivate mit zentraler dopaminerger aktivität |
HU227759B1 (en) | 1994-08-23 | 2012-02-28 | Smithkline Beecham Plc | Improved pharmaceutical formulations containing ibuprofen and codeine |
ATE247114T1 (de) | 1994-09-12 | 2003-08-15 | Lilly Co Eli | Serotonergische modulatoren |
FR2727682A1 (fr) | 1994-12-02 | 1996-06-07 | Pf Medicament | Nouveaux derives de 3,5-dioxo-(2h,4h)-1,2,4-triazines, leur preparation et leur application a titre de medicament |
US5552412A (en) * | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
US5883094A (en) * | 1995-04-24 | 1999-03-16 | Pfizer Inc. | Benzimidazolone derivatives with central dopaminergic activity |
US5854290A (en) * | 1995-09-21 | 1998-12-29 | Amy F. T. Arnsten | Use of guanfacine in the treatment of behavioral disorders |
US6083947A (en) * | 1996-01-29 | 2000-07-04 | The Regents Of The University Of California | Method for treating sexual dysfunctions |
GB9613423D0 (en) | 1996-06-26 | 1996-08-28 | Lilly Industries Ltd | Pharmaceutical compounds |
US5916916A (en) * | 1996-10-10 | 1999-06-29 | Eli Lilly And Company | 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods |
ATE271379T1 (de) * | 1996-11-06 | 2004-08-15 | Wockhardt Europ Ltd | System zur verzögerten freisetzung säurelabiler substanzen |
EP0942728A1 (en) * | 1996-12-02 | 1999-09-22 | MERCK SHARP & DOHME LTD. | Use of nk-1 receptor antagonists for treating sexual dysfunction |
US5859246A (en) | 1997-01-30 | 1999-01-12 | Neurogen Corporation | 1-phenyl-4-benzylpiperazines: dopamine receptor subtype specific ligands |
US20040023948A1 (en) * | 1997-03-24 | 2004-02-05 | Green Richard David | Fast-dispersing dosage form containing 5-HT1 agonists |
GB9706089D0 (en) | 1997-03-24 | 1997-05-14 | Scherer Ltd R P | Pharmaceutical composition |
RU2193880C2 (ru) * | 1997-06-11 | 2002-12-10 | Дзе Проктер Энд Гэмбл Компани | Покрытая пленкой таблетка улучшенной безопасности для верхних отделов желудочно-кишечного тракта |
ATE241341T1 (de) * | 1997-09-10 | 2003-06-15 | Takeda Chemical Industries Ltd | Stabilisierte pharmazeutische zusammensetzung |
SE9703375D0 (sv) | 1997-09-18 | 1997-09-18 | Astra Ab | A new combination |
CH692199A8 (fr) * | 1997-10-09 | 2002-06-14 | Cermol S.A. | Composes pyridiques et compositions pharmaceutique |
JP3724157B2 (ja) * | 1997-10-30 | 2005-12-07 | コニカミノルタホールディングス株式会社 | 映像観察装置 |
FR2775188B1 (fr) * | 1998-02-23 | 2001-03-09 | Lipha | Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption |
AU4068599A (en) | 1998-05-20 | 1999-12-06 | Schering Corporation | Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction |
EP1077704A4 (en) | 1998-05-21 | 2002-01-30 | Lilly Co Eli | COMBINATION THERAPY FOR TREATING DEPRESSION |
US20020151543A1 (en) * | 1998-05-28 | 2002-10-17 | Sepracor Inc. | Compositions and methods employing R (-) fluoxetine and other active ingredients |
US6068846A (en) * | 1998-08-05 | 2000-05-30 | Melaleuca, Incorporated | Methods and materials for treating depression and mood disorder |
EP0982030A3 (en) * | 1998-08-17 | 2000-05-10 | Pfizer Products Inc. | 2,7-substituted octahydro-pyrrolo 1,2-a]pyrazine derivatives as 5ht 1a ligands |
UA67802C2 (uk) | 1998-10-23 | 2004-07-15 | Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. | Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції |
AU1738900A (en) | 1998-11-19 | 2000-06-05 | Nortran Pharmaceuticals Inc. | Serotonin ligands as pro-erectile compounds |
US6680071B1 (en) * | 1999-03-03 | 2004-01-20 | R. P. Scherer Technologies, Inc. | Opioid agonist in a fast dispersing dosage form |
WO2000063189A1 (en) | 1999-04-16 | 2000-10-26 | Novo Nordisk A/S | Crystalline r- guanidines, arginine or (l) -arginine (2s) -2- ethoxy -3-{4- [2-(10h -phenoxazin -10-yl)ethoxy]phenyl}propanoate |
JP2002542287A (ja) | 1999-04-28 | 2002-12-10 | レスピラトリウス アクチボラゲット | 医 薬 |
IT1312310B1 (it) | 1999-05-07 | 2002-04-15 | Recordati Ind Chimica E Farma | Uso di antagonisti selettivi del recettore adrenergico a 1b per ilmiglioramento della disfunzione sessuale |
US6579968B1 (en) | 1999-06-29 | 2003-06-17 | Palatin Technologies, Inc. | Compositions and methods for treatment of sexual dysfunction |
US6346548B1 (en) | 1999-08-16 | 2002-02-12 | Cephalon, Inc. | Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue |
IT1313625B1 (it) * | 1999-09-22 | 2002-09-09 | Boehringer Ingelheim Italia | Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina. |
CN1396829A (zh) * | 2000-02-24 | 2003-02-12 | 法玛西雅厄普约翰美国公司 | 新的药物联合形式 |
IL152781A0 (en) | 2000-06-28 | 2003-06-24 | Pfizer Prod Inc | Melanocortin receptor ligands |
US6521623B1 (en) * | 2000-09-19 | 2003-02-18 | Boehringer Ingelheim Pharma Kg | N,N'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors |
US6586435B2 (en) * | 2000-09-19 | 2003-07-01 | Boehringer Ingelheim Pharma Kg | Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors |
ATE341538T1 (de) | 2000-09-19 | 2006-10-15 | Boehringer Ingelheim Pharma | Benzimidazolonderivate mit affinität zu serotonin-und dopaminrezeptoren |
ATE358483T1 (de) | 2000-11-22 | 2007-04-15 | Abbott Lab | Selektive dopamin-d4-rezeptoragonisten zur behandlung von sexuellen dysfunktionen |
GB0105893D0 (en) | 2001-03-09 | 2001-04-25 | Pfizer Ltd | Pharmaceutically active compounds |
EE200300469A (et) | 2001-03-28 | 2004-02-16 | Pfizer Inc. | N-fenpropüültsüklopentüülasendatud glutaramiidi derivaadid kui NEP inhibiitorid FSAD puhul |
DK1256343T3 (da) * | 2001-05-11 | 2006-10-30 | Juergen K Dr Beck | Flibanserin til behandlingen af extrapyramidale bevægelseslidelser |
US6627646B2 (en) * | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
US7115628B2 (en) | 2001-07-18 | 2006-10-03 | Merck & Co., Inc. | Bridged piperidine derivatives as melanocortin receptor agonists |
DE60223031T2 (de) | 2001-07-30 | 2008-07-24 | Spectrum Pharmaceuticals, Inc., Irvine | Arylpiperazin gebundene tetrahydroindolonderivate |
CA2450093C (en) | 2001-08-02 | 2008-09-23 | Bidachem S.P.A. | Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments |
US7183410B2 (en) * | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
US20030060475A1 (en) * | 2001-08-10 | 2003-03-27 | Boehringer Ingelheim Pharma Kg | Method of using flibanserin for neuroprotection |
DE10138273A1 (de) | 2001-08-10 | 2003-02-27 | Boehringer Ingelheim Pharma | Arzneimittel mit neuroprotektiver Wirkung |
HUP0202719A3 (en) * | 2001-08-21 | 2006-01-30 | Pfizer Prod Inc | Pharmaceutical compositions for the treatment of female sexual dysfunctions |
DE10149674A1 (de) * | 2001-10-09 | 2003-04-24 | Apogepha Arzneimittel Gmbh | Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung |
UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
DE10209982A1 (de) * | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma | Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe |
MEP55308A (en) | 2002-05-22 | 2011-05-10 | Boehringer Ingelheim Pharma | New pharmaceutical compositions containing flibanserin polymorph a |
US20040048877A1 (en) * | 2002-05-22 | 2004-03-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions containing flibanserin |
CN1674877A (zh) * | 2002-06-07 | 2005-09-28 | 兰贝克赛实验室有限公司 | 控释的多单位药物释放系统 |
US20040116532A1 (en) * | 2002-09-13 | 2004-06-17 | Craig Heacock | Pharmaceutical formulations of modafinil |
US20040132697A1 (en) * | 2002-11-06 | 2004-07-08 | Pfizer Inc. | Treatment of female sexual dysfunction |
GB0225908D0 (en) | 2002-11-06 | 2002-12-11 | Pfizer Ltd | Treatment of female sexual dysfunction |
US20040147581A1 (en) | 2002-11-18 | 2004-07-29 | Pharmacia Corporation | Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy |
US20040193452A1 (en) * | 2003-01-06 | 2004-09-30 | Laura Berman | Method and system for computerized sexual function assessment of female users |
WO2004069339A1 (en) | 2003-01-29 | 2004-08-19 | Psychogenics Inc. | Treatment for attention-deficit hyperactivity disorder |
US20050037983A1 (en) | 2003-03-11 | 2005-02-17 | Timothy Dinan | Compositions and methods for the treatment of depression and other affective disorders |
WO2004095266A2 (en) * | 2003-04-24 | 2004-11-04 | International Business Machines Corporation | Executable file creation |
US20050065158A1 (en) * | 2003-07-16 | 2005-03-24 | Pfizer Inc. | Treatment of sexual dysfunction |
JP2007516949A (ja) | 2003-07-16 | 2007-06-28 | ファイザー・インク | 性機能不全の治療 |
WO2005044238A1 (en) | 2003-11-07 | 2005-05-19 | Ranbaxy Laboratories Limited | Modified release solid dosage form of amphetamine salts |
BRPI0510074A (pt) * | 2004-04-22 | 2007-10-16 | Boehringer Ingelheim Int | composições farmacêuticas para o tratamento de distúrbios sexuais ii |
US20050239798A1 (en) | 2004-04-22 | 2005-10-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for the treatment of premenstrual and other female sexual disorders |
US20060014757A1 (en) * | 2004-07-14 | 2006-01-19 | Boehringer Ingelheim Pharmaceuticals | Method for the treatment of anorexia nervosa |
US20060025420A1 (en) * | 2004-07-30 | 2006-02-02 | Boehringer Ingelheimn International GmbH | Pharmaceutical compositions for the treatment of female sexual disorders |
WO2006024471A1 (en) * | 2004-09-03 | 2006-03-09 | Boehringer Ingelheim International Gmbh | Method for the treatment of attention deficit hyperactivity disorder |
WO2006096439A2 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases |
CA2599721A1 (en) | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of depression |
WO2006096434A2 (en) | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders |
WO2006119884A2 (en) * | 2005-05-06 | 2006-11-16 | Boehringer Ingelheim International Gmbh | Method for the treatment of drug abuse with flibanserin |
US20060258640A1 (en) * | 2005-05-13 | 2006-11-16 | Boehringer Ingelheim International Gmbh | Use of Flibanserin in the treatment of chronic pain |
EP1888070A1 (en) * | 2005-05-19 | 2008-02-20 | Boehringer Ingelheim International GmbH | Method for the treatment of sexual dysfunctions due to medical conditions |
JP2008540673A (ja) * | 2005-05-19 | 2008-11-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 薬剤誘発性性機能不全の治療方法 |
ES2646326T3 (es) | 2005-08-03 | 2017-12-13 | Sprout Pharmaceuticals, Inc. | Uso de flibanserina en el tratamiento de la obesidad |
HU227490B1 (en) * | 2005-08-26 | 2011-07-28 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Sustained release pharmaceutical preparation containing carvedilol |
US20070123540A1 (en) * | 2005-10-29 | 2007-05-31 | Angelo Ceci | Sexual desire enhancing medicaments comprising benzimidazolone derivatives |
CA2626134C (en) | 2005-10-29 | 2013-12-24 | Boehringer Ingelheim International Gmbh | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
US20070105869A1 (en) * | 2005-11-08 | 2007-05-10 | Stephane Pollentier | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders |
CA2640382C (en) * | 2006-01-27 | 2015-12-29 | Eurand, Inc | Drug delivery systems comprising weakly basic drugs and organic acids |
US20090023712A1 (en) * | 2006-02-18 | 2009-01-22 | Boehringer Ingelheim International Gmbh | Pharmaceutical Compositions for the Treatment of Attention Deficit Hyperactivity Disorder Comprising Flibanserin |
US20090176698A1 (en) * | 2006-02-20 | 2009-07-09 | Boehringer Ingelheim International Gmbh | Benzimidazolone Derivatives for the Treatment of Urinary Incontinence |
US20090247546A1 (en) * | 2006-02-28 | 2009-10-01 | Boehringer Ingelheim International Gmbh | Treatment of Prevention of Valvular Heart Disease with Flibanserin |
JP2009536176A (ja) * | 2006-05-09 | 2009-10-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 閉経後の性的欲求障害の治療のためのフリバンセリンの使用 |
DE602007004615D1 (de) | 2006-06-30 | 2010-03-18 | Boehringer Ingelheim Pharma | Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen |
WO2008006838A1 (en) | 2006-07-14 | 2008-01-17 | Boehringer Ingelheim International Gmbh | Use of flibanserin for the treatment of sexual disorders in females |
CA2657045A1 (en) * | 2006-07-14 | 2008-01-17 | Boehringer Ingelheim International Gmbh | Combinations of flibanserin with caffeine, process for their preparation and use thereof as medicaments |
JP2008040352A (ja) * | 2006-08-09 | 2008-02-21 | Seiko Epson Corp | 液体現像剤、液体現像剤の製造方法、画像形成方法、および画像形成装置 |
CL2007002214A1 (es) * | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
AR062320A1 (es) * | 2006-08-14 | 2008-10-29 | Boehringer Ingelheim Int | Formulaciones de flibanserina y metodo para fabricarlas |
EA200900270A1 (ru) | 2006-08-25 | 2009-08-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Системы регулируемого высвобождения и способ их приготовления |
EP2129400A2 (en) | 2007-03-28 | 2009-12-09 | Boehringer Ingelheim International GmbH | Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders |
-
2007
- 2007-08-10 EA EA200900270A patent/EA200900270A1/ru unknown
- 2007-08-10 JP JP2009525011A patent/JP5220746B2/ja active Active
- 2007-08-10 BR BRPI0716436A patent/BRPI0716436B8/pt active IP Right Grant
- 2007-08-10 AU AU2007287639A patent/AU2007287639A1/en not_active Abandoned
- 2007-08-10 MX MX2009002031A patent/MX2009002031A/es active IP Right Grant
- 2007-08-10 AR ARP070103545A patent/AR062321A1/es unknown
- 2007-08-10 WO PCT/EP2007/058302 patent/WO2008022932A2/en active Application Filing
- 2007-08-10 KR KR1020097006149A patent/KR20090045945A/ko not_active Application Discontinuation
- 2007-08-10 CN CN201510127785.3A patent/CN104721168A/zh active Pending
- 2007-08-10 EP EP07802563A patent/EP2056797A2/en not_active Withdrawn
- 2007-08-10 CN CNA2007800316337A patent/CN101505736A/zh active Pending
- 2007-08-10 CA CA2661613A patent/CA2661613C/en not_active Expired - Fee Related
- 2007-08-13 US US11/837,962 patent/US8512748B2/en active Active
- 2007-08-13 CL CL200702358A patent/CL2007002358A1/es unknown
- 2007-08-13 PE PE2007001080A patent/PE20080738A1/es not_active Application Discontinuation
- 2007-08-13 TW TW096129885A patent/TW200817053A/zh unknown
-
2008
- 2008-12-22 ZA ZA200810781A patent/ZA200810781B/xx unknown
-
2009
- 2009-01-08 NO NO20090100A patent/NO20090100L/no not_active Application Discontinuation
- 2009-02-19 IL IL197129A patent/IL197129A/en active IP Right Grant
- 2009-02-25 CO CO09019210A patent/CO6150131A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
BRPI0716436B8 (pt) | 2021-05-25 |
IL197129A0 (en) | 2009-11-18 |
BRPI0716436B1 (pt) | 2020-05-19 |
WO2008022932A2 (en) | 2008-02-28 |
ZA200810781B (en) | 2009-10-28 |
CN104721168A (zh) | 2015-06-24 |
EA200900270A1 (ru) | 2009-08-28 |
WO2008022932A3 (en) | 2008-07-24 |
US8512748B2 (en) | 2013-08-20 |
CA2661613A1 (en) | 2008-02-28 |
EP2056797A2 (en) | 2009-05-13 |
CL2007002358A1 (es) | 2008-04-18 |
CA2661613C (en) | 2016-01-26 |
IL197129A (en) | 2014-08-31 |
BRPI0716436A2 (pt) | 2014-03-04 |
AU2007287639A1 (en) | 2008-02-28 |
JP5220746B2 (ja) | 2013-06-26 |
US20080069873A1 (en) | 2008-03-20 |
NO20090100L (no) | 2009-04-23 |
CO6150131A2 (es) | 2010-04-20 |
TW200817053A (en) | 2008-04-16 |
CN101505736A (zh) | 2009-08-12 |
AR062321A1 (es) | 2008-10-29 |
JP2010501511A (ja) | 2010-01-21 |
KR20090045945A (ko) | 2009-05-08 |
MX2009002031A (es) | 2009-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20080738A1 (es) | Sistema de liberacion controlada y metodo para fabricarlo | |
DOP2016000132A (es) | Sistema de administración farmacologico | |
PE20080423A1 (es) | Formulaciones de flibanserina y metodo para fabricarlas | |
BRPI0711784B8 (pt) | dispositivo de embolização construído de polímero expansível e seu método de preparação | |
AR070543A1 (es) | Sistema y metodo de fluido de tratamiento con rompedor oxidante | |
AR092957A1 (es) | Formulacion de forma farmaceutica solida de desintegracion veloz que comprende carbonato de calcio funcionalizado y metodo para su fabricacion | |
CO7151506A2 (es) | Formulación de fármaco de liberación retardada | |
AR048862A1 (es) | Aparatos y metodos para el suministro transdermico de una vacuna antigripal | |
AR094422A1 (es) | Concentración de suspensiones | |
AR072685A1 (es) | Composicion topica para el tratamiento de queratosis actinica | |
PA8815901A1 (es) | Sistema de administracion de drogas con efecto estabilizante | |
AR072359A1 (es) | Encapsulacion de agentes biologicamente activos | |
AR071737A1 (es) | Un metodo para producir geles de adapaleno | |
CO6620070A2 (es) | Uso de polimidas en el tratamiento de formaciones subterraneas | |
CU20160055A7 (es) | Formulación de fármaco de liberación retardada | |
PE20110876A1 (es) | Formulacion de deposito de octreotida con niveles de exposicion constantemente altos | |
BR112021017878A2 (pt) | Carbonato de magnésio com superfície reagida, sistema de liberação, formulação de cuidados domiciliares, métodos para preparar um carbonato de magnésio com superfície reagida e para preparar um sistema de liberação, e, uso de um carbonato de magnésio com superfície reagida e de um sistema de liberação | |
CY1116840T1 (el) | Χρηση 24-norudca | |
AR079409A1 (es) | Preparaciones antihelminticas granuladas y sistemas de suninistros | |
WO2014124029A3 (en) | System and method for delivering protease inhibitors | |
CL2008003002A1 (es) | Composición farmacéutica inyectable intravenosa en forma de emulsión aceite en agua que comprende al toxoide larotaxel (xrp9881) o cabazitaxel (xrp6258) disuelto en lecitina, y al tensioactivo aniónico fosfatidilglicerol o acido fosfatidico; proeceidimiento para su preparacion, útil como antineoplástico. | |
BR112018009839A8 (pt) | método para cimentar revestimento em um furo de poço e sistema para cimentar revestimento em um furo de poço | |
EA201891159A1 (ru) | Наносистемы для контролируемого транспорта активных молекул диагностического, прогностического и терапевтического назначения | |
ES2626069T3 (es) | Adhesivos multicomponente, fabricación de los mismos, y aplicaciones de los mismos | |
RU2007136310A (ru) | Способ получения наноразмерной системы доставки лекарственных средств на основе диоксида кремния |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |